NCT04401982View on ClinicalTrials.gov

Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

February 22, 2022

Study Completion Date

February 22, 2022

Conditions
Ocular HypertensionSuspect Glaucoma
Interventions
DRUG

Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks

Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered

Trial Locations (4)

20902

Maryland Eye Consultants and Surgeons, Silver Spring

21201

University of Maryland Medical Center, Baltimore

University Physicians Inc., Baltimore

Maryland

"UM Faculty Physicians, Inc. , 5900 Waterloo Crossing"

Sponsors

Collaborators (1)

Aerie Pharmaceuticals
All Listed Sponsors
collaborator

Aerie Pharmaceuticals

INDUSTRY

lead

University of Maryland, Baltimore

OTHER

NCT04401982 - Measuring the Effects of Rhopressa on Episcleral and Retinal Blood Flow in Ocular Hypertension and Glaucoma Suspects | Biotech Hunter | Biotech Hunter